Literature DB >> 8803889

A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE).

D D Gladman1, M B Urowitz, A Ong, J Gough, A MacKinnon.   

Abstract

The aim of the present investigation was to assess and compare health status instruments in SLE. One hundred and twenty-five patients completed five health status instruments: the Health Assessment Questionnaire (HAQ), Functional Ability Index, the Fatigue Severity Scale (FSS), the Disability Days Measure (DDM), the Centre for Epidemiological Studies-Depression Scale (CES-D), and the Medical Outcomes Study (MOS) Short Form Health Survey during their Clinic visit. Disease activity was measured using the SLE Disease Activity Index (SLEDAI). All instruments described a spectrum of quality of life outcomes in these patients. An inter-instrument correlation analysis revealed that components of the MOS correlated significantly with each of the other instruments used. There was no correlation between any of the instruments used and the SLEDAI. We conclude that health status assessment as measured by the MOS short form is a valid independent outcome measure in patients with SLE.

Entities:  

Mesh:

Year:  1996        PMID: 8803889     DOI: 10.1177/096120339600500305

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  13 in total

1.  Health-related quality of life assessed by LupusQoL questionnaire and SF-36 in Turkish patients with systemic lupus erythematosus.

Authors:  Sibel Yilmaz-Oner; Can Oner; Fatih Mert Dogukan; Toklong Filam Moses; Kubra Demir; Nazar Tekayev; Pamir Atagunduz; Serhan Tuglular; Haner Direskeneli
Journal:  Clin Rheumatol       Date:  2015-04-07       Impact factor: 2.980

2.  BMI, disease activity, and health-related quality-of-life in systemic lupus erythematosus.

Authors:  Li-Wei Zhu; Tao Zhang; Hai-Feng Pan; Xiang-Pei Li; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2010-05-02       Impact factor: 2.980

3.  Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil.

Authors:  Eutília A M Freire; Inês O Maia; Jamile C A Nepomuceno; Rozana M Ciconelli
Journal:  Clin Rheumatol       Date:  2007-01-10       Impact factor: 2.980

Review 4.  [Systemic lupus erythematosus--activity and outcome].

Authors:  M Aringer; J Smolen
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

Review 5.  Quality-of-life measurements versus disease activity in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

Review 6.  Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: cross-cultural issues.

Authors:  Sergio M A Toloza; Meenakshi Jolly; Graciela S Alarcón
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

7.  Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis.

Authors:  Vinod Chandran; Sita Bhella; Catherine Schentag; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2007-02-26       Impact factor: 19.103

Review 8.  Clinical outcome measures for cutaneous lupus erythematosus.

Authors:  J Albrecht; V P Werth
Journal:  Lupus       Date:  2010-08       Impact factor: 2.911

9.  Endogenous type-I interferon activity is not associated with depression or fatigue in systemic lupus erythematosus.

Authors:  Erinn S Kellner; Pui Y Lee; Yi Li; Juliana Switanek; Haoyang Zhuang; Mark S Segal; Eric S Sobel; Minoru Satoh; Westley H Reeves
Journal:  J Neuroimmunol       Date:  2010-04-22       Impact factor: 3.478

10.  Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist.

Authors:  C Grootscholten; G Ligtenberg; R H W M Derksen; K M G Schreurs; J W de Glas-Vos; E C Hagen; A W L van den Wall Bake; T W J Huizinga; F H J van den Hoogen; M Bijl; J C van Houwelingen; F J Snoek; J H M Berden
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.